Page 63 - Read Online

Lyons et al. Cancer Drug Resist 2021;4:745-54 https://dx.doi.org/10.20517/cdr.2021.37 Page 753

given the high attrition rate of promising candidate molecules as they progressively develop from the
laboratory to the clinic. For practical reasons, we are not suggesting that these new techniques completely
replace existing experimental approaches, but they should be considered and applied to some extent to
rigorously explore key ADC development milestones. Improvements in the methods employed to more
stringently test and assess the in vivo performance of any candidate drug or ADC can only stand to enable
more informed “go, no go” decisions earlier in their development and ultimately ensure that efforts and
resources are focused on those candidate molecules identified as most likely to succeed in the clinic and
benefit cancer patients.

DECLARATIONS
Acknowledgement
The authors would like to thank Dr. Youngkyu Park and Dr. Dave Tuveson (Figure 1C) and Joseph Merrill
and Libia Garcia (Figure 2), for kindly providing images used in both figures.

Authors’ contributions
Contributed to the written content and review of this manuscript: Lyons SK, Plenker D, Trotman LC

Availability of data and materials
Not applicable.

Financial support and sponsorship
This work was supported by grants (NIH/NCI RO1 5R01CA237154-02) - Trotman, NIH/NCI CSHL Cancer
Center Support Grant 5P30CA45508-33 (Tuveson) - Trotman and Lyons, and by the German Research
Foundation (DFG) (PL 894/1-1) - Plenker.

Ethical approval and consent to participate
Not applicable.

Conflicts of Interest
All authors declared that there are no conflicts of interest.

Consent for publication
The authors (Lyons SK, Plenker D, and Trotman LC) consent for Cancer Drug Resistance to publish our
manuscript entitled “Advances in preclinical evaluation of experimental antibody drug conjugates”.

Copyright
© The Author(s) 2021.

REFERENCES
1. Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51. DOI PubMed
2. Ulaner GA, Hyman DM, Ross DS, et al. Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer
using 89Zr-trastuzumab PET/CT. J Nucl Med 2016;57:1523-8. DOI PubMed PMC
3. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics 2019;20:273-86. DOI
PubMed PMC
4. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-
2018. JAMA 2020;323:844-53. DOI PubMed PMC
5. Hingorani AD, Kuan V, Finan C, et al. Improving the odds of drug development success through human genomics: modelling study.
Sci Rep 2019;9:18911. DOI PubMed PMC
6. Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity.
Adv Drug Deliv Rev 2015;91:3-6. DOI PubMed
7. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23. DOI PubMed
8. Tuveson D, Clevers H. Cancer modeling meets human organoid technology. Science 2019;364:952-5. DOI PubMed